BWXT Medical announced today that it entered into a long-term, mutually exclusive agreement to manufacture Boston Scientific’s TheraSphere.
Ottawa, Ontario-based BWXT’s new deal with Boston Scientific covers manufacturing of the TheraSphere Y-90 glass microspheres from the Marlborough, Mass.-based medtech company.
TheraSphere treatment for patients with hepatocellular carcinoma (HCC) delivers millions of glass microspheres containing radioactive Yttrium-90 directly to liver tumors through a catheter with minimal exposure to surrounding healthy tissue, according to a news release.
Under the agreement, BWXT Medical, a subsidiary of BWX Technologies, will invest to automate the manufacturing process at its Ottawa plant to increase capacity and dependability to match the growing global demand for TheraSphere.
“We congratulate Boston Scientific on its recent receipt of FDA PMA approval of TheraSphere, which expands patient access to this unique technology,” BWXT Medical president Martyn Coombs said in the release. “We share the aspiration of making a significant difference in the lives of people suffering with cancer, and we look forward to continuing to build a strong supply chain foundation for future growth.”